TrialBJU international2016

Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.

Ravi A Madan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.